Drugs / MEDI-557
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 missed | ||||||
| Phase 1 | NCT01475305 | Oct → Dec 2011 | respiratory syncytial virus infectious disease | MedImmune LLC | Terminated | Missed primary Stop: Enrollment |
| Phase 1 | NCT00578682 | Dec 2007 → Oct 2010 | — | MedImmune LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01562938 Comparator | Mar 2012 → May 2013 | respiratory syncytial virus infectious disease | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI-557 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01562938 ↗ |
| Modality | Monoclonal antibody | “a Humanized Monoclonal Antibody” NCT01562938 ↗ |
| Route | Intravenous | “Single IV dose of 3 mg/kg MEDI-557” NCT00578682 ↗ |